Want to join the conversation?
$ONCE and $PFE said FDA granted breakthrough therapy designation to SPK-9001, which is being investigated in ongoing Phase 1/2 trial as potential one-time therapy, to treat rare genetic bleeding disorder hemophilia B. The designation is intended to expedite development and FDA review of drugs to treat serious or life-threatening disease.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?